Slow progress toward a better type of health care https://t.co/k2sZIl9IDj — The Propell Group (@ThePropellGroup) August 8, 2016 #healthtech
“Global Healthcare – 13 Deals, Investments & Transactions – Week 31, 2016” https://t.co/s1q4lyKBUI by @ThePropellGroup @galengrowthasia
0 0
“Global Healthcare – 13 Deals, Investments & Transactions – Week 31, 2016” https://t.co/s1q4lyKBUI by @ThePropellGroup @galengrowthasia — The Propell Group [...]
Clinical trials, mental health, medication adherence, in 500 Startups’ new digital health class https://t.co/2LT19iZyAH via @MobiHealthNews
0 0
Clinical trials, mental health, medication adherence, in 500 Startups’ new digital health class https://t.co/2LT19iZyAH via @MobiHealthNews — The Propell Group (@ThePropellGroup) August 8, [...]
Investing: The great escape https://t.co/7Wp4NpkCcf via @FT — The Propell Group (@ThePropellGroup) August 8, 2016 #healthtech
Healthcare 2.0: Four Macro Trends Changing How Healthcare Is Delivered https://t.co/kV7z75EQ2H — The Propell Group (@ThePropellGroup) August 7, 2016 #healthtech
Fitbit poaches digital health VP from Walgreens to realize healthcare vision – MedCity News https://t.co/GZByHalBoi
0 0
Fitbit poaches digital health VP from Walgreens to realize healthcare vision – MedCity News https://t.co/GZByHalBoi — The Propell Group (@ThePropellGroup) August 7, 2016 #healthtech
A Q&A with Verily’s CTO about the Galvani joint venture with GSK – MedCity News https://t.co/t8HRlGxWay
0 0
A Q&A with Verily’s CTO about the Galvani joint venture with GSK – MedCity News https://t.co/t8HRlGxWay — The Propell Group (@ThePropellGroup) August 6, 2016 #healthtech
Poop pill’s surprise failure shows that the microbiome is still a mystery https://t.co/S8zOOV4s0L
0 0
Poop pill’s surprise failure shows that the microbiome is still a mystery https://t.co/S8zOOV4s0L — The Propell Group (@ThePropellGroup) August 6, 2016 #healthtech
US health insurers: knock on wood https://t.co/cNPBAiepA3 via @FT — The Propell Group (@ThePropellGroup) August 6, 2016 #healthtech
Bristol-Myers’ value plunges $23bn after cancer drug fails trial https://t.co/nec1FK2q2C via @FT — The Propell Group (@ThePropellGroup) August 6, 2016 #healthtech